{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:55:58Z","timestamp":1780570558451,"version":"3.54.1"},"update-to":[{"DOI":"10.1002\/14651858.cd012915","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T00:00:00Z","timestamp":1556582400000}}],"reference-count":96,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012915.pub2","type":"journal-article","created":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T22:38:26Z","timestamp":1556663906000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["MVA85A vaccine to enhance BCG for preventing tuberculosis"],"prefix":"10.1002","volume":"2019","author":[{"given":"Rufaro","family":"Kashangura","sequence":"first","affiliation":[{"name":"Nhlangano Health Centre; Box 29 Nhlangano Swaziland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Jullien","sequence":"additional","affiliation":[{"name":"Jigme Dorji Wangchuck National Referral Hospital; Thimphu Bhutan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Garner","sequence":"additional","affiliation":[{"name":"Liverpool School of Tropical Medicine; Department of Clinical Sciences; Pembroke Place Liverpool Merseyside UK L3 5QA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Johnson","sequence":"additional","affiliation":[{"name":"Liverpool School of Tropical Medicine; Department of Clinical Sciences; Pembroke Place Liverpool Merseyside UK L3 5QA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,4,30]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD012915.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S2213-2600(17)30060-7","article-title":"Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study","volume":"5","author":"Andrews","year":"2017","journal-title":"Lancet Respiratory Medicine"},{"issue":"7","key":"10.1002\/14651858.CD012915.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"778","DOI":"10.5588\/ijtld.16.0709","article-title":"Impact of isoniazid preventive therapy on the evaluation of long-term effectiveness of infant MVA85A vaccination","volume":"21","author":"Bunyasi","year":"2017","journal-title":"International Journal Tuberculosis and Lung Disease"},{"issue":"3","key":"10.1002\/14651858.CD012915.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S2213-2600(15)00037-5","article-title":"Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial","volume":"3","author":"Ndiaye","year":"2015","journal-title":"Lancet Respiratory Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012915.pub2-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1093\/cid\/cix834","article-title":"Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette-Guerin (BCG) for infants of HIV infected mothers: a Phase 2 randomized controlled trial","volume":"66","author":"Nemes","year":"2018","journal-title":"Clinical Infectious Diseases"},{"issue":"12","key":"10.1002\/14651858.CD012915.pub2-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1093\/infdis\/jir195","article-title":"Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants","volume":"203","author":"Scriba","year":"2011","journal-title":"Journal of Infectious Diseases"},{"issue":"9871","key":"10.1002\/14651858.CD012915.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(13)60177-4","article-title":"Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial","volume":"381","author":"Tameris","year":"2013","journal-title":"Lancet"},{"issue":"8","key":"10.1002\/14651858.CD012915.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"e2921","DOI":"10.1371\/journal.pone.0002921","article-title":"Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa","volume":"3","author":"Brookes","year":"2008","journal-title":"PLOS One"},{"issue":"11","key":"10.1002\/14651858.CD012915.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"e0141623","DOI":"10.1371\/journal.pone.0141623","article-title":"Evaluation of Xpert(R) MTB\/RIF assay in induced sputum and gastric lavage samples from young children with suspected tuberculosis from the MVA85A TB vaccine trial","volume":"10","author":"Bunyasi","year":"2015","journal-title":"PLOS One"},{"issue":"6","key":"10.1002\/14651858.CD012915.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"e67177","DOI":"10.1371\/journal.pone.0067177","article-title":"Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naive subjects gives comparable immunogenicity to one dose in ART plus subjects","volume":"8","author":"Dieye","year":"2013","journal-title":"PLOS One"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0010|cit10","unstructured":"Harris S Meyer J Satti I Kosotv M Rowland R Poulton ID Comparison of the safety and immunogenicity of a candidate TB vaccine, MVA85A, given by the intramuscular or intradermal route in BCG-vaccinated adults Annual Congress of the British-Society-for-Immunology 2011 55"},{"issue":"8","key":"10.1002\/14651858.CD012915.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1093\/infdis\/jit647","article-title":"Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate tuberculosis vaccine, MVA85A, alone and in combination","volume":"209","author":"Harris","year":"2014","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0012|cit12","doi-asserted-by":"crossref","unstructured":"Hawkridge T Scriba TJ Gelderbloem S Smit E Tameris M Moyo M Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa Journal of Infectious disease 2008 544 52","DOI":"10.1086\/590185"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0013|cit13","unstructured":"Matsumiya M Immune response to MVA85A or placebo in BCG-vaccinated South African infants at days 0 and 28 post-vaccination Arrayexpress-repository, V1 2014"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0014|cit14","doi-asserted-by":"crossref","unstructured":"Matsumiya M Harris SA Satti I Stockdale L Tanner R O\u2019Shea MK Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell response Biomed Central Infectious Diseases 2014 314","DOI":"10.1186\/1471-2334-14-314"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0015|cit15","unstructured":"Matsumiya M GSE56559: immune response to MVA85A or placebo in BCG-vaccinated South African infants at day 1 post-vaccination Arrayexpress-repository, V1 2014"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0016|cit16","doi-asserted-by":"crossref","unstructured":"McShane H Pathan AA Sander CR Keating SM Gilbert SC Huygen K Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans Nature Medicine 2004 1240 4","DOI":"10.1038\/nm1128"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0017|cit17","doi-asserted-by":"crossref","unstructured":"Meyer J Harris S. A Satti I Poulton ID Poyintz HC Tanner R Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery Vaccine 2013 1026 33","DOI":"10.1016\/j.vaccine.2012.12.042"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0018|cit18","doi-asserted-by":"crossref","unstructured":"Minassian AM Rowland R Beveridge NE Poulton ID Satti I Harris S A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults BrItish Medical Journal 2015 e000223","DOI":"10.1136\/bmjopen-2011-000223"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0019|cit19","doi-asserted-by":"crossref","unstructured":"Minhinnick A Satti I Harris S Wilkie M Sheehan S Stockdale L A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults Vaccine 1412 21","DOI":"10.1016\/j.vaccine.2016.01.062"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0020|cit20","doi-asserted-by":"crossref","unstructured":"MulengaH Tameris MD Luabeya KK Geldenhuys H Scriba TJ Hussey GD The Role of Clinical Symptoms in the Diagnosis of Intrathoracic Tuberculosis in Young Children Pediatric Infectious Diseases Journal 1157 62","DOI":"10.1097\/INF.0000000000000847"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0021|cit21","doi-asserted-by":"crossref","unstructured":"Odutola AA Owolabi OA Owiafe PK Mcshane H Ota MO A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants Vaccine 2012 5591 4","DOI":"10.1016\/j.vaccine.2012.06.054"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0022|cit22","doi-asserted-by":"crossref","unstructured":"Ota MO Odutola AA Owiafe PK Donkor S Owolabi OA Brittain NJ Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants Sci. Transl. Med. 2011 88ra56","DOI":"10.1126\/scitranslmed.3002461"},{"issue":"10","key":"10.1002\/14651858.CD012915.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"e1052","DOI":"10.1371\/journal.pone.0001052","article-title":"Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials","volume":"2","author":"Pathan","year":"2007","journal-title":"PLOS One"},{"issue":"38","key":"10.1002\/14651858.CD012915.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1016\/j.vaccine.2012.06.084","article-title":"Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults","volume":"30","author":"Pathan","year":"2012","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.trivac.2012.07.001","article-title":"A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity","volume":"1","author":"Rowland","year":"2012","journal-title":"Trials in vaccinology"},{"issue":"1","key":"10.1002\/14651858.CD012915.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"50","DOI":"10.4161\/hv.22464","article-title":"Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial","volume":"9","author":"Rowland","year":"2013","journal-title":"Human Vaccines and Immunotherapeutics"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1164\/rccm.200809-1486OC","article-title":"Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals","volume":"179","author":"Sander","year":"2009","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1473-3099(14)70845-X","article-title":"Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial","volume":"14","author":"Satti","year":"2014","journal-title":"Lancet Infectious diseases"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/eji.200939754","article-title":"Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells","volume":"40","author":"Scriba","year":"2010","journal-title":"European Journal of Immunology"},{"issue":"7","key":"10.1002\/14651858.CD012915.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1164\/rccm.201108-1548OC","article-title":"A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and\/or Mycobacterium tuberculosis-infected adults","volume":"185","author":"Scriba","year":"2012","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"11","key":"10.1002\/14651858.CD012915.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"e0141687","DOI":"10.1371\/journal.pone.0141687","article-title":"A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults","volume":"10","author":"Sheehan","year":"2015","journal-title":"PLOS One"},{"issue":"2","key":"10.1002\/14651858.CD012915.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"e87340","DOI":"10.1371\/journal.pone.0087340","article-title":"The candidate TB vaccine, MVA85A, induces highly durable Th1 responses","volume":"9","author":"Tameris","year":"2014","journal-title":"PLOS One"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1186\/s12879-014-0660-7","article-title":"Serum indoleamine 2,3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A","volume":"14","author":"Tanner","year":"2014","journal-title":"Biomed Central Infectious Diseases"},{"issue":"11","key":"10.1002\/14651858.CD012915.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"e5934","DOI":"10.1371\/journal.pone.0005934","article-title":"Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A","volume":"10","author":"Whelan","year":"2009","journal-title":"PLOS One"},{"issue":"37","key":"10.1002\/14651858.CD012915.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1-372, v-vi","DOI":"10.3310\/hta17370","article-title":"Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Gu\u00e9rin vaccination against tuberculosis","volume":"17","author":"Abubakar","year":"2013","journal-title":"Health Technology Assessment"},{"issue":"7","key":"10.1002\/14651858.CD012915.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.3390\/v6072735","article-title":"Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases","volume":"6","author":"Altenburg","year":"2014","journal-title":"Viruses"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1741-7015-9-81","article-title":"The impact of diabetes on tuberculosis treatment outcomes: a systematic review","volume":"9","author":"Baker","year":"2011","journal-title":"BMC Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012915.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/S1472-9792(12)70009-4","article-title":"Rational approach to selection and clinical development of TB vaccine candidates","volume":"92","author":"Barker","year":"2012","journal-title":"Tuberculosis"},{"issue":"9885","key":"10.1002\/14651858.CD012915.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1016\/S0140-6736(13)61481-6","article-title":"Tuberculosis vaccine trials","volume":"381","author":"Behr","year":"2013","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD012915.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1002\/eji.200737504","article-title":"Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations","volume":"37","author":"Beveridge","year":"2007","journal-title":"European Journal of Immunology"},{"issue":"3","key":"10.1002\/14651858.CD012915.pub2-BIB0041|cit41","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006404.pub2","article-title":"Artesunate plus pyronaridine for treating uncomplicated Plasmodium falciparum malaria","author":"Bukirwa","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4 Pt 1","key":"10.1002\/14651858.CD012915.pub2-BIB0042|cit42","first-page":"1376","article-title":"Diagnostic standards and classification of tuberculosis in adults and children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America","volume":"161","author":"Centers for Disease Control and Prevention","year":"2000","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"j5845","DOI":"10.1136\/bmj.j5845","article-title":"Oxford TB vaccine study calls into question selective use of animal data","volume":"360","author":"Cohen","year":"2018","journal-title":"BMJ"},{"issue":"1 Pt 1","key":"10.1002\/14651858.CD012915.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1542\/peds.96.1.29","article-title":"The efficacy of bacillus Calmette-Gu\u00e9rin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature","volume":"96","author":"Colditz","year":"1995","journal-title":"Paediatrics"},{"issue":"12","key":"10.1002\/14651858.CD012915.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1080\/09540121.2012.672719","article-title":"Social constraints to TB\/HIV healthcare: accounts from coinfected patients in South Africa","volume":"24","author":"Daftary","year":"2012","journal-title":"AIDS Care"},{"issue":"7","key":"10.1002\/14651858.CD012915.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1128\/CVI.00047-10","article-title":"Investigating the induction of vaccine-induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG-immunized adults vaccinated with a new tuberculosis vaccine, MVA85A","volume":"17","author":"Cassan","year":"2010","journal-title":"Clinical and Vaccine Immunology"},{"issue":"44","key":"10.1002\/14651858.CD012915.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"6116","DOI":"10.1016\/j.vaccine.2009.08.031","article-title":"BCG vaccination reduces risk of infection with Mycobacterium tuberculosis as detected by gamma interferon release assay","volume":"27","author":"Eisenhut","year":"2009","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1038\/ncomms3748","article-title":"Mechanism of inhibition of Mycobacterium tuberculosis antigen 85 by ebselen","volume":"4","author":"Favrot","year":"2013","journal-title":"Nature Communications"},{"issue":"2","key":"10.1002\/14651858.CD012915.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.1093\/infdis\/jis008","article-title":"Evaluation of tuberculosis diagnostics in children: 1. Proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panel","volume":"205","author":"Graham","year":"2012","journal-title":"Journal of Infectious Diseases"},{"issue":"8","key":"10.1002\/14651858.CD012915.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"e23463","DOI":"10.1371\/journal.pone.0023463","article-title":"Th1\/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85A","volume":"6","author":"Griffiths","year":"2011","journal-title":"PLOS One"},{"issue":"5-6","key":"10.1002\/14651858.CD012915.pub2-BIB0051|cit51","first-page":"415","article-title":"Tuberculosis","volume":"100","author":"Harries","year":"2006","journal-title":"Annals of Tropical Medicine and Parasitology"},{"issue":"7","key":"10.1002\/14651858.CD012915.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1128\/CVI.00128-14","article-title":"Process of assay selection and optimization for the study of case and control samples from a phase IIb efficacy trial of a candidate tuberculosis vaccine, MVA85A","volume":"21","author":"Harris","year":"2014","journal-title":"Clinical and Vaccine Immunology"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0053|cit53","unstructured":"Higgins JP Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"8","key":"10.1002\/14651858.CD012915.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1473-3099(06)70552-7","article-title":"Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design","volume":"6","author":"Ibanga","year":"2006","journal-title":"Lancet Infectious Diseases"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0055|cit55","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Clinical safety data management: definitions and standards for expedited reporting E2A.1994. ICH harmonised tripartite guideline. Current Step 4 version dated 27 October 1994 www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E2A\/Step4\/E2A_Guideline.pdf"},{"issue":"6","key":"10.1002\/14651858.CD012915.pub2-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1093\/ije\/dyv142","article-title":"Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review","volume":"44","author":"Kashangura","year":"2015","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0057|cit57","unstructured":"Loke YK Price D Herxheimer A Chapter 14: Adverse effects. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0058|cit58","first-page":"A5487","article-title":"A phase I trial evaluating aerosol administration of a candidate TB vaccine, MVA85A, as a way to induce potent local cellular immune responses and avoid anti-vector immunity","volume":"193","author":"Manjaly","year":"2016","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012915.pub2-BIB0059|cit59","first-page":"392","article-title":"The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era","volume":"8","author":"Marais","year":"2004","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"issue":"7","key":"10.1002\/14651858.CD012915.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"e67922","DOI":"10.1371\/journal.pone.0067922","article-title":"Roles for Treg expansion and HMGB1 signaling through the TLR1-2-6 axis in determining the magnitude of the antigen-specific immune response to MVA85A","volume":"8","author":"Matsumiya","year":"2013","journal-title":"PLOS One"},{"issue":"2","key":"10.1002\/14651858.CD012915.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.tube.2013.11.003","article-title":"A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data","volume":"94","author":"McShane","year":"2014","journal-title":"Tuberculosis"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"k236","DOI":"10.1136\/bmj.k236","article-title":"Helen McShane and colleagues reply to Deborah Cohen","volume":"360","author":"McShane","year":"2018","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0063|cit63","unstructured":"NCT00395720 The safety and immunogenicity of a TB vaccine; MVA85A, in healthy volunteers who are infected with HIV clinicaltrials.gov\/ct2\/show\/NCT00395720"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0064|cit64","unstructured":"NCT00423566 A phase I study of the safety and immunogenicity of a recombinant MVA vaccine encoding a secreted antigen from M. tuberculosis , antigen 85A, delivered intradermally by a needle injection in healthy volunteers clinicaltrials.gov\/ct2\/show\/NCT00423566"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0065|cit65","unstructured":"NCT00423839 A phase I study of the safety and immunogenicity of MVA85A in healthy Gambian volunteers clinicaltrials.gov\/ct2\/show\/NCT00423839"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0066|cit66","unstructured":"NCT00427453 A phase I study of the safety and immunogenicity of a recombinant MVA vaccine encoding a secreted antigen from M. tuberculosis , antigen 85A, delivered intradermally by a needle injection in healthy volunteers who have received BCG immunisation 1 month previously clinicaltrials.gov\/ct2\/show\/NCT00427453"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0067|cit67","unstructured":"NCT00427830 A phase I study of the safety and immunogenicity of a recombinant MVA vaccine encoding a secreted antigen from M. tuberculosis , antigen 85A, delivered intradermally by a needle injection in healthy volunteers who have previously received BCG clinicaltrials.gov\/ct2\/show\/NCT00427830"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0068|cit68","unstructured":"NCT00456183 Safety and immunogenicity of MVA85A in volunteers latently infected with TB clinicaltrials.gov\/ct2\/show\/NCT00456183"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0069|cit69","unstructured":"NCT00460590 Safety and immunogenicity of MVA85A, in healthy volunteers in Cape Town clinicaltrials.gov\/ct2\/show\/NCT00460590"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0070|cit70","unstructured":"NCT00465465 A study of 2 doses of a new TB vaccine, MVA85A, in healthy volunteers previously vaccinated with BCG clinicaltrials.gov\/ct2\/show\/NCT00465465"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0071|cit71","unstructured":"NCT00480454 Safety, immunogenicity, and impact of MVA85A, on the immunogenicity of the EPI vaccines clinicaltrials.gov\/ct2\/show\/NCT00480454"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0072|cit72","unstructured":"NCT00480558 A study of MVA85A, in asymptomatic volunteers infected with TB, HIV or both clinicaltrials.gov\/ct2\/show\/NCT00480558"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0073|cit73","unstructured":"NCT00548444 T-cell turnover following vaccination with MVA85A clinicaltrials.gov\/ct2\/show\/NCT00548444"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0074|cit74","unstructured":"NCT00653770 A phase I study to assess the safety and immunogenicity of tuberculosis (TB) vaccine candidates FP85A and MVA85A clinicaltrials.gov\/ct2\/show\/NCT00653770"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0075|cit75","unstructured":"NCT00731471 A phase I study of a new tuberculosis (TB) vaccine, MVA85A, in healthy volunteers with HIV clinicaltrials.gov\/ct2\/show\/NCT00731471"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0076|cit76","unstructured":"NCT00953927 A study of MVA85A in healthy infants clinicaltrials.gov\/ct2\/show\/NCT00953927"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0077|cit77","unstructured":"NCT01181856 Safety of tuberculosis vaccine, MVA85A, administered by the intramuscular route and the intradermal route clinicaltrials.gov\/ct2\/show\/NCT01181856"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0078|cit78","unstructured":"NCT01194180 A BCG challenge model study to assess anti-mycobacterial immunity induced by BCG and a candidate TB vaccine, MVA85A clinicaltrials.gov\/ct2\/show\/NCT01194180"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0079|cit79","unstructured":"NCT01497769 Safety of tuberculosis vaccine, MVA85A, administered by the aerosol route and the intradermal route clinicaltrials.gov\/ct2\/show\/NCT01497769"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0080|cit80","unstructured":"NCT01683773 Safety study of tuberculosis vaccines AERAS-402 and MVA85A clinicaltrials.gov\/ct2\/show\/NCT01683773"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0081|cit81","unstructured":"NCT01829490 Safety study of ChAdOx185A vaccination with and without MVA85A boost in healthy adults clinicaltrials.gov\/show\/NCT01829490"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0082|cit82","unstructured":"NCT01879163 Phase I trial evaluating safety and immunogenicity of MVA85A-IMX313 compared to MVA85A in BCG vaccinated adults clinicaltrials.gov\/ct2\/show\/NCT01879163"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0083|cit83","unstructured":"NCT01954563 Study evaluating aerosol and intradermal administration of a candidate tuberculosis (TB) vaccine, MVA85A, as a way to increase immune response and avoid anti-vector immunity clinicaltrials.gov\/ct2\/show\/NCT01954563"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0084|cit84","unstructured":"NCT02532036 MVA85A aerosol versus intramuscular vaccination in adults with latent Mycobacterium tuberculosis (M. tb) Infection clinicaltrials.gov\/show\/NCT02532036"},{"issue":"7","key":"10.1002\/14651858.CD012915.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"158","DOI":"10.4172\/2157-7560.1000158","article-title":"Differential cytokine levels in adults induced by a novel candidate TB boost vaccine, MVA85A-according to previous BCG vaccination status","volume":"3","author":"Owiafe","year":"2012","journal-title":"Journal of Vaccines & Vaccination"},{"issue":"4","key":"10.1002\/14651858.CD012915.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMra1008049","article-title":"Tuberculosis in children","volume":"367","author":"Perez-Velez","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0087|cit87","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1016\/j.vaccine.2005.12.066","article-title":"Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85a from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. Tuberculosis H37Rv","volume":"24","author":"Romano","year":"2006","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"g4643","DOI":"10.1136\/bmj.g4643","article-title":"Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis","volume":"349","author":"Roy","year":"2014","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0090|cit90","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G Oxman A GRADE handbook for grading quality of evidence and strength of recommendations Available from guidelinedevelopment.org\/handbook October 2013"},{"issue":"3","key":"10.1002\/14651858.CD012915.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1378\/chest.12-0142","article-title":"Relevance of latent TB infection in areas of high TB prevalence","volume":"142","author":"Sharma","year":"2012","journal-title":"Chest"},{"issue":"4","key":"10.1002\/14651858.CD012915.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"e17601","DOI":"10.1371\/journal.pone.0017601","article-title":"Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review","volume":"6","author":"Tiemersma","year":"2011","journal-title":"PLOS One"},{"issue":"5","key":"10.1002\/14651858.CD012915.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"e0005440","DOI":"10.1371\/journal.pntd.0005440","article-title":"The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: an open-label trial","volume":"11","author":"Wajja","year":"2017","journal-title":"PLOS Neglected Tropical Diseases"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0094|cit94","unstructured":"World Health Organization Global tuberculosis report 2018 www.who.int\/tb\/publications\/global_report\/en\/"},{"key":"10.1002\/14651858.CD012915.pub2-BIB0095|cit95","unstructured":"Uppsala Monitoring Centre WHO adverse reaction terminology (WHO-ART) www.who-umc.org\/vigibase\/services\/learn-more-about-who-art\/"},{"issue":"1","key":"10.1002\/14651858.CD012915.pub2-BIB0096|cit96","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012915","article-title":"MVA85A vaccine to enhance BCG for preventing tuberculosis","author":"Kashangura","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD012915.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:05:44Z","timestamp":1769385944000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012915.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Infectious Diseases Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,4,30]]},"references-count":96,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012915.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,30]]}}}